References
- The Swedish Medical Products Agency. Information from the Swedish. Medical Products Agency 1994; 6, 94. Stockholm, (In Swedish)
- Scott W G, Cooper B C, Scott M. Pharmacoeconmic evaluation of roxithromycin versus amoxycillin/clavulanic acid in community-acquired lower respiratory tract infection study. Infection 23 Suppl 1995; 1: 21–24
- Scott W G, Tilyard M W, Dovey S M, Cooper B, Scott H M. Roxithromycin versus cefaclor in lower respiratory tract infection. A general practice pharmacoeconomic study. PharmacoEconomics 1993; 4: 122–130
- Paulsen O, Christenson B A, Hebelka M, Ljungberg B, Nilsson-Ehle I, Nyman L, Svensson R, Tüll P, Varga Z. Efficacy and tolerance of roxithromycin in comparison with erythromycin stearate in patients with lower respiratory tract infections. Scand J Infect Dis 1992; 24: 219–225
- Federation of County Councils. Cost per admitted patient, bed-day, physician visit etc., 1993. Stockholm 1995, (In Swedish)
- Druginformation Ltd. Pharmaceutical specialties in Sweden. 93, FASS 93. Stockholm 1993, (In Swedish)
- The National Corporation of Swedish Pharmacies. Swedish pharmaceutical statistics 94, I Nordenstam, M Wennberg, K Kristoferson, 1995, (In Swedish)
- Grassi C, Bartucci F, Sassella D. Efficacy and safety of roxithromycin in respiratory tract infections. Br J Clin Pract Suppl 1988; 55: 104–106
- Peterslund N, Hanninen P, Schreiner A, Black F T, Hult V. Roxithromycin in the treatment of pneumonia. J Antimicrob Chemother 1989; 23: 737–741
- Kaku M, Kohno S, Kogo H, Ishida K, Hara K. Efficacy of roxithromycin in the treatment of mycoplasma pneumonia. Chemotherapy 1995; 41(2)149–152